245 related articles for article (PubMed ID: 37945750)
21. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
[TBL] [Abstract][Full Text] [Related]
22. Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
Walker LC; Krause L; ; Spurdle AB; Waddell N
Breast Cancer Res Treat; 2012 Aug; 134(3):1005-11. PubMed ID: 22434526
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer genomic signature offers prognostic value.
Troutman SM; Price DK; Figg WD
Cancer Biol Ther; 2010 Dec; 10(11):1079-80. PubMed ID: 21088497
[TBL] [Abstract][Full Text] [Related]
24. Genomic determinants of somatic copy number alterations across human cancers.
Zhang Y; Xu H; Frishman D
Hum Mol Genet; 2016 Mar; 25(5):1019-30. PubMed ID: 26732428
[TBL] [Abstract][Full Text] [Related]
25. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.
Robbins CM; Tembe WA; Baker A; Sinari S; Moses TY; Beckstrom-Sternberg S; Beckstrom-Sternberg J; Barrett M; Long J; Chinnaiyan A; Lowey J; Suh E; Pearson JV; Craig DW; Agus DB; Pienta KJ; Carpten JD
Genome Res; 2011 Jan; 21(1):47-55. PubMed ID: 21147910
[TBL] [Abstract][Full Text] [Related]
26. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
27. Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype.
Simpson BS; Camacho N; Luxton HJ; Pye H; Finn R; Heavey S; Pitt J; Moore CM; Whitaker HC
Commun Biol; 2020 Aug; 3(1):440. PubMed ID: 32796921
[TBL] [Abstract][Full Text] [Related]
28. A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome.
Ashcraft KA; Johnson-Pais TL; Troyer DA; Hernandez J; Leach RJ
Urol Oncol; 2020 Dec; 38(12):932.e1-932.e7. PubMed ID: 32665124
[TBL] [Abstract][Full Text] [Related]
29. Identifying the driver miRNAs with somatic copy number alterations driving dysregulated ceRNA networks in cancers.
Dou R; Kang S; Yang H; Zhang W; Zhang Y; Liu Y; Ping Y; Pang B
Biol Direct; 2023 Nov; 18(1):79. PubMed ID: 37993951
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of methods for identifying somatic copy number alterations from deep sequencing data.
Alkodsi A; Louhimo R; Hautaniemi S
Brief Bioinform; 2015 Mar; 16(2):242-54. PubMed ID: 24599115
[TBL] [Abstract][Full Text] [Related]
31. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.
Williams JL; Greer PA; Squire JA
Cancer Genet; 2014; 207(10-12):474-88. PubMed ID: 25434580
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma.
Tsuyukubo T; Ishida K; Osakabe M; Shiomi E; Kato R; Takata R; Obara W; Sugai T
Mol Carcinog; 2020 Apr; 59(4):412-424. PubMed ID: 32039517
[TBL] [Abstract][Full Text] [Related]
33. Molecular correlates of intermediate- and high-risk localized prostate cancer.
Ye H; Sowalsky AG
Urol Oncol; 2018 Aug; 36(8):368-374. PubMed ID: 30103901
[TBL] [Abstract][Full Text] [Related]
34. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
Bramhecha YM; Rouzbeh S; Guérard KP; Scarlata E; Brimo F; Chevalier S; Hamel L; Aprikian AG; Lapointe J
Mod Pathol; 2019 Jan; 32(1):128-138. PubMed ID: 30140035
[TBL] [Abstract][Full Text] [Related]
35. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.
Zhang N; Harbers L; Simonetti M; Diekmann C; Verron Q; Berrino E; Bellomo SE; Longo GMC; Ratz M; Schultz N; Tarish F; Su P; Han B; Wang W; Onorato S; Grassini D; Ballarino R; Giordano S; Yang Q; Sapino A; Frisén J; Alkass K; Druid H; Roukos V; Helleday T; Marchiò C; Bienko M; Crosetto N
Nat Commun; 2024 Apr; 15(1):3475. PubMed ID: 38658552
[TBL] [Abstract][Full Text] [Related]
36. COPS: a sensitive and accurate tool for detecting somatic Copy Number Alterations using short-read sequence data from paired samples.
Krishnan NM; Gaur P; Chaudhary R; Rao AA; Panda B
PLoS One; 2012; 7(10):e47812. PubMed ID: 23110103
[TBL] [Abstract][Full Text] [Related]
37. Somatic DNA copy number alterations and their potential clinical utility for predicting lethal prostate cancer.
Liu W; Wang L; Xu J
Asian J Androl; 2013 Sep; 15(5):586-7. PubMed ID: 23817503
[No Abstract] [Full Text] [Related]
38. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
39. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
40. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
Res Sq; 2023 Feb; ():. PubMed ID: 36865331
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
